» Articles » PMID: 16107180

Schizophrenia and Comorbid Substance Use Disorder: Effects of Antipsychotics

Overview
Specialty Psychiatry
Date 2005 Aug 19
PMID 16107180
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

The rate of comorbid substance use disorder in patients with schizophrenia is 3 times higher than that in the general population. Men with schizophrenia appear to be particularly vulnerable to substance use disorders. Substances commonly abused in patients with schizophrenia include alcohol, cannabis, and cocaine. Although the basis of comorbidity is unclear, a number of theories have been proposed, including the possibility of a deficiency in the dopamine-mediated mesocorticolimbic brain reward circuit. Data suggest that substance abuse may complicate and worsen the course of schizophrenia. Early intervention with appropriate pharmacotherapy may prove beneficial and potentially improve the long-term course of the disorder. Conventional antipsychotics have not been overly useful in this patient population, but some atypical antipsychotics have been shown to reduce the use of alcohol, cannabis, cocaine, and tobacco in patients with schizophrenia. Further research is required, but early evidence suggests that at least some atypical antipsychotics may prove to be therapeutically effective in the treatment of patients with schizophrenia and comorbid substance use disorder.

Citing Articles

Antipsychotic Medication Influences the Discriminative Value of Acylethanolamides as Biomarkers of Substance Use Disorder.

Herrera-Imbroda J, Flores-Lopez M, Requena-Ocana N, Araos P, Ropero J, Garcia-Marchena N Int J Mol Sci. 2023; 24(11).

PMID: 37298321 PMC: 10253203. DOI: 10.3390/ijms24119371.


Psychomotor Symptoms in Chronic Cocaine Users: An Interpretative Model.

Cenci D, Carbone M, Callegari C, Maremmani I Int J Environ Res Public Health. 2022; 19(3).

PMID: 35162918 PMC: 8835199. DOI: 10.3390/ijerph19031897.


The Long-Term Changes in Dynamic Risk and Protective Factors Over Time in a Nationwide Sample of Dutch Forensic Psychiatric Patients.

Jankovic M, Van Boxtel G, Masthoff E, De Caluwe E, Bogaerts S Front Psychiatry. 2021; 12:737846.

PMID: 34603110 PMC: 8481688. DOI: 10.3389/fpsyt.2021.737846.


Co-Occurring Psychiatric and Substance Use Disorders: Clinical Survey Among a Rural Cohort of Italian Patients.

Milano G, Vergani H, Cattedra S, Carrozzino R, Mattioli F, Robbiano L Neuropsychiatr Dis Treat. 2020; 15:3453-3459.

PMID: 31908460 PMC: 6927221. DOI: 10.2147/NDT.S222567.


The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review.

Batalla A, Janssen H, Gangadin S, Bossong M J Clin Med. 2019; 8(7).

PMID: 31330972 PMC: 6678854. DOI: 10.3390/jcm8071058.